Timber Pharmaceuticals Receives Notice of Allowance from U.S. Patent and Trademark Office for BPX-01 and BPX-04
September 15 2020 - 8:00AM
via NEWMEDIAWIRE -- Timber Pharmaceuticals, Inc. ("Timber" or the
“Company”) (NYSE American: TMBR), a biopharmaceutical company
focused on the development and commercialization of treatments for
orphan dermatologic diseases, today announced that it has received
a formal notice of allowance from the U.S. Patent and Trademark
Office (USPTO) for the Company’s patent application covering its
pharmaceutical tetracycline (including minocycline) compositions
for dermatological use (U.S. Patent Application No.: 16/514,459).
“The notice of allowance from the USPTO further
protects our dermatology portfolio,” said John Koconis, Chief
Executive Officer of Timber. “Our stable topical composition of
minocycline is the result of many years of research and development
and has the potential to reduce side effects associated with oral
systemic delivery in the treatment of dermatologic conditions.”
This notice confirms the allowance of additional
claims relative to the Company’s BPX-01 and BPX-04 assets including
the Company’s method for treating an active dermatological
inflammation or infection, including acne or rosacea, by applying
the topical compositions to an inflamed or infected area of skin at
least once daily for a period of at least one month.
Timber previously announced its intention to
evaluate its proprietary topical programs, BPX-01 and BPX-04, in
the treatment of inflammatory lesions of acne vulgaris and
papulopustular rosacea for a strategic partnership, co-development
or other non-dilutive value creation strategy. Timber believes the
expansion of claims for this patent will further protect these
assets.
About Timber Pharmaceuticals, Inc.
Timber Pharmaceuticals, Inc. is a
biopharmaceutical company focused on the development and
commercialization of treatments for orphan dermatologic diseases.
The Company's investigational therapies have proven
mechanisms-of-action backed by decades of clinical experience and
well-established CMC (chemistry, manufacturing and control) and
safety profiles. The Company is initially focused on developing
non-systemic treatments for rare dermatologic diseases including
congenital ichthyosis (CI), facial angiofibromas (FAs) in tuberous
sclerosis complex (TSC), and localized scleroderma. For more
information, visit https://www.timberpharma.com/.
Forward-Looking Statements
This press release contains certain
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934 and Private Securities Litigation Reform Act, as
amended, including those relating to the Company's product
development, clinical and regulatory timelines, market opportunity,
competitive position, possible or assumed future results of
operations, business strategies, potential growth opportunities and
other statements that are predictive in nature. These
forward-looking statements are based on current expectations,
estimates, forecasts and projections about the industry and markets
in which we operate and management's current beliefs and
assumptions.
These statements may be identified by the use of
forward-looking expressions, including, but not limited to,
"expect," "anticipate," "intend," "plan," "believe," "estimate,"
"potential, "predict," "project," "should," "would" and similar
expressions and the negatives of those terms. These statements
relate to future events or our financial performance and involve
known and unknown risks, uncertainties, and other factors which may
cause actual results, performance or achievements to be materially
different from any future results, performance or achievements
expressed or implied by the forward-looking statements. Such
factors include those set forth in the Company's Form 10-Q filed on
August 18, 2020 and its other filings with the Securities and
Exchange Commission. Prospective investors are cautioned not to
place undue reliance on such forward-looking statements, which
speak only as of the date of this press release. The Company
undertakes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events or
otherwise.
For more information, contact:
Timber Pharmaceuticals, Inc. John Koconis Chief
Executive Officer jkoconis@timberpharma.com
Investor Relations: Stephanie Prince PCG Advisory (646) 762-4518
sprince@pcgadvisory.com
Media Relations: Adam Daley Berry & Company Public Relations
(212) 253-8881adaley@berrypr.com
Timber Pharmaceuticals (AMEX:TMBR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Timber Pharmaceuticals (AMEX:TMBR)
Historical Stock Chart
From Apr 2023 to Apr 2024